Tempest Therapeutics Inc (TPST) Quarterly Institutional 13F Update (Q2 2026)

Biotech Tempest Therapeutics (TPST) disclosed a finance leadership change: Justin Trojanowski is resigning as the company's principal financial and accounting officer, effective September 1, 2026. Nicholas Rossettos steps into the role the same day, taking on the CFO title along with treasurer and corporate secretary duties. Rossettos, 60, is a CPA with over 30 years of finance experience, largely in biopharma, including a recent stint as interim CFO of Sernova Corp. The filing doesn't give a reason for Trojanowski's departure.

AI summary pending

AI summary pending

AI summary pending

Tempest Therapeutics (ticker TPST) filed an 8-K that mentions a shareholder vote (Item 5.07), but says the results are covered in another item (Item 8.01) that isn’t included in this excerpt. So the filing basically says “a vote happened” without giving any numbers or outcomes. It’s an incomplete disclosure.

Tempest Therapeutics entered into a collaboration agreement with Heibei Senlang Biotechnology to develop its CAR-T product candidate TPST-4003. The partnership starts with an investigator-initiated trial in China for myasthenia gravis and multiple sclerosis, with first patient dosing expected in the fourth quarter of 2026. Tempest will pay development fees of $1.5 million to $2.0 million per product and retains full ownership of its intellectual property. Senlang will have an option to license the product for China after trial data is delivered.